Morgan Stanley Reiterates Equal-Weight Rating on Erasca, Inc. (ERAS)

Market Context

Erasca, Inc. operates in the Healthcare sector. The stock currently trades at $18.82 with a market capitalization of $958.9M. The stock has gained 1231.2% over the past 52 weeks.

Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Erasca, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Erasca, Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 20, 2026	Morgan Stanley	Equal-Weight	N/A
Jul 14, 2026	B of A Securities	Neutral	N/A
Jun 04, 2026	B of A Securities	Neutral	N/A
May 12, 2026	Mizuho	Outperform	N/A
Apr 27, 2026	Stifel	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View ERAS Stock Page